Gene
CCND3
CCND3 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (8), Actionable biomarkers (1), Trial mentions (7), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CCND3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 2 at the structurally incomplete recent edge.
CCND3 has 7 trial mentions across 7 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 5 of 11,460 | 0.04% |
| 2022 | 1 of 8,285 | 0.01% | 12 of 13,598 | 0.09% |
| 2021 | 0 of 8,692 | 0.00% | 5 of 15,045 | 0.03% |
| 2020 | 1 of 7,640 | 0.01% | 12 of 14,459 | 0.08% |
| 2019 | 1 of 7,300 | 0.01% | 14 of 12,159 | 0.12% |
| 2018 | 1 of 6,927 | 0.01% | 10 of 11,854 | 0.08% |
| 2017 | 1 of 6,558 | 0.02% | 8 of 11,595 | 0.07% |
Showing 10 of 37 years.
Assay-provider ledger (8)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Illumina | Unclassified | Clinical validationAnalytical validation | 1 | March 11, 2014 |
| Agilent | Reagent supplier | Clinical validationAnalytical validation | 1 | June 15, 2011 |
| Oxford Gene Technology | Unclassified | Clinical validationAnalytical validation | 1 | June 15, 2011 |
| AB Applied Biosystems | Reagent supplier | Clinical validation | 1 | January 01, 2010 |
| BIO-RAD Laboratories S.A. (trypan blue) | Reagent supplier | Clinical validation | 1 | January 01, 2010 |
Showing 5 of 8 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CCND3 amplification | Cdk4/6 Inhibitors | response-associated | No disease recorded | Cancer Genome Interpreter |
Trial mentions (7)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT04040205 | Trial eligibility (AACT) |
| NCT03452774 | Trial eligibility (AACT) |
| NCT05497076 | Trial eligibility (AACT) |
| NCT02187783 | Trial eligibility (AACT) |
| NCT02896335 | Trial eligibility (AACT) |
Showing 5 of 7 trial mentions.
Target-disease associations (388)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 2-methoxyresorcinol sulfate measurement | measurement | GWAS credible sets |
| 22q11.2 deletion syndrome | cardiovascular disease | Mouse knockout (IMPC) |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Autoimmune lymphoproliferative syndrome with recurrent viral infections | genetic, familial or congenital disease | Mouse knockout (IMPC) |
| B-cell acute lymphoblastic leukemia | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 388 associations.
Vendor sourcing (24)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Alliance for Clinical Trials in Oncology | Trial sponsor | Mentioned in trial textTrial free-text mention | CCND3 | View trial NCT02523014 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.52G>A (p.D18N) alteration is located in exon 1 (coding exon 1) of the CCND3 gene. This alteration results from a G to A substitution at nucleotide posi... | View ClinVar record SCV003583973.2 |
| Brain Science Foundation | Trial collaborator | Mentioned in trial textTrial free-text mention | CCND3 | View trial NCT02523014 |
| Centre Léon Bérard | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Male or female patients aged of at least 18 years on day of signing informed consent. * Patients with histologically confirmed diagnosis of metastatic d... | View trial NCT04116541 |
| Centre Léon Bérard | Trial sponsor | Mentioned in trial textTrial free-text mention | CCND3 | View trial NCT04116541 |
Showing 5 of 24 sourcing records.
Trial-cited literature (119)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Clinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups. | British journal of haematology | 2025 | 2 |
| Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). | JCO precision oncology | 2024 | 16 |
| Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials. | International journal of cancer | 2023 | 22 |
| Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. | Blood cancer journal | 2023 | 16 |
| Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial. | Cancer communications (London, England) | 2023 | 11 |
Showing 5 of 119 papers.
Protein variant mentions (2)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.G719X | 1 | 2013 | PMID 24100924 |
| p.Y40C | 1 | 2022 | PMID 36275715 |
Literature-extracted relations (12)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| PROPRANOLOL | Chemical | negative_correlate |
Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. | 2010 |
| EVEROLIMUS | Chemical | negative_correlate |
Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. | 2006 |
| Neoplasms | Disease | associate |
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). | 2024 |
| Neoplasms | Disease | associate |
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials. | 2023 |
| Leukemia, Hairy Cell | Disease | associate |
Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders. | 2022 |
Showing 5 of 12 relation assertions.
Organizations publishing (179)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Mayo Clinic | Hospital | 11 | 2009 to 2024 |
| Dana-Farber Cancer Institute | Other | 9 | 2012 to 2022 |
| Government of the United States of America | Government | 8 | 2010 to 2024 |
| Memorial Sloan Kettering Cancer Center | Hospital | 7 | 2013 to 2021 |
| Harvard Medical School | Academic | 6 | 2015 to 2018 |
Showing 5 of 179 organizations.
Where CCND3 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
- respiratory or thoracic disease
362 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.